Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference
Tevogen Bio (Nasdaq: TVGN) announced it will host an AI panel during the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The panel, titled 'AI in Biopharma: Next Frontier of Medical Innovation,' will feature speakers from Microsoft and Tevogen.AI discussing how artificial intelligence can transform drug discovery, development timelines, patient accessibility, and reduce operating costs.
The event will take place on January 13, 2025, at the Marines' Memorial Club & Hotel, featuring panelists including Microsoft's Global Chief Medical Officer Dr. David Rhew, Tevogen.AI's CIO Mittul Mehta, and Rubix Health's Dr. Sean Tunis. The session will highlight Tevogen.AI's use of advanced AI capabilities in developing precision T cell therapies for infectious diseases, cancers, and neurological disorders.
Tevogen Bio (Nasdaq: TVGN) ha annunciato che ospiterà un panel sull'IA durante la 43a Conferenza Annuale J.P. Morgan Healthcare a San Francisco. Il panel, intitolato 'IA in Biopharma: la prossima frontiera dell'innovazione medica,' avrà come relatori esperti di Microsoft e Tevogen.AI che discuteranno di come l'intelligenza artificiale possa trasformare la scoperta dei farmaci, i tempi di sviluppo, l'accessibilità per i pazienti e ridurre i costi operativi.
L'evento si svolgerà il 13 gennaio 2025, al Marines' Memorial Club & Hotel, con panelist tra cui il Chief Medical Officer Globale di Microsoft, il Dr. David Rhew, il CIO di Tevogen.AI, Mittul Mehta, e il Dr. Sean Tunis di Rubix Health. La sessione metterà in evidenza l'uso delle avanzate capacità di IA da parte di Tevogen.AI nello sviluppo di terapie cellulari T di precisione per malattie infettive, tumori e disturbi neurologici.
Tevogen Bio (Nasdaq: TVGN) anunció que organizará un panel sobre IA durante la 43ª Conferencia Anual de Atención Médica de J.P. Morgan en San Francisco. El panel, titulado 'IA en Biopharma: la próxima frontera de la innovación médica,' contará con oradores de Microsoft y Tevogen.AI que discutirán cómo la inteligencia artificial puede transformar el descubrimiento de fármacos, los cronogramas de desarrollo, la accesibilidad para los pacientes y reducir los costos operativos.
El evento tendrá lugar el 13 de enero de 2025, en el Marines' Memorial Club & Hotel, con panelistas que incluyen al Chief Medical Officer Global de Microsoft, el Dr. David Rhew, el CIO de Tevogen.AI, Mittul Mehta, y el Dr. Sean Tunis de Rubix Health. La sesión destacará el uso de capacidades avanzadas de IA por parte de Tevogen.AI en el desarrollo de terapias de células T de precisión para enfermedades infecciosas, cánceres y trastornos neurológicos.
Tevogen Bio (Nasdaq: TVGN)은 샌프란시스코에서 열리는 제43회 J.P. Morgan 헬스케어 컨퍼런스에서 AI 패널을 개최한다고 발표했습니다. 'AI in Biopharma: 의료 혁신의 다음 프론티어'라는 제목의 패널에는 Microsoft와 Tevogen.AI의 연사들이 참여하여 인공지능이 약물 발견, 개발 일정, 환자 접근성 변화를 어떻게 이끌어낼 수 있는지와 운영 비용 절감에 대해 논의합니다.
이 행사는 2025년 1월 13일에 Marines' Memorial Club & Hotel에서 열리며, Microsoft의 글로벌 최고 의료 책임자인 David Rhew 박사, Tevogen.AI의 CIO인 Mittul Mehta, Rubix Health의 Sean Tunis 박사가 패널리스트로 참여합니다. 세션에서는 감염병, 암 및 신경 장애를 위한 정밀 T세포 치료 개발에 있어서 Tevogen.AI의 첨단 AI 활용 사례가 강조됩니다.
Tevogen Bio (Nasdaq: TVGN) a annoncé qu'elle accueillera un panel sur l'IA lors de la 43ème Conférence Annuelle J.P. Morgan Healthcare à San Francisco. Le panel, intitulé 'IA en Biopharma : la prochaine frontière de l'innovation médicale,' comprendra des intervenants de Microsoft et Tevogen.AI qui discuteront de la manière dont l'intelligence artificielle peut transformer la découverte de médicaments, les délais de développement, l'accessibilité pour les patients et réduire les coûts d'exploitation.
L'événement aura lieu le 13 janvier 2025, au Marines' Memorial Club & Hotel, avec des intervenants tels que le Chief Medical Officer Mondial de Microsoft, Dr. David Rhew, le CIO de Tevogen.AI, Mittul Mehta, et Dr. Sean Tunis de Rubix Health. La session mettra en avant l'utilisation par Tevogen.AI de capacités avancées d'IA dans le développement de thérapies cellulaires T de précision pour les maladies infectieuses, le cancer et les troubles neurologiques.
Tevogen Bio (Nasdaq: TVGN) hat angekündigt, dass es während der 43. jährlichen J.P. Morgan Healthcare Conference in San Francisco ein AI-Panel veranstalten wird. Das Panel mit dem Titel 'KI in Biopharma: Die nächste Grenze medizinischer Innovation' wird Sprecher von Microsoft und Tevogen.AI umfassen, die erörtern, wie künstliche Intelligenz die Arzneimittelentdeckung, Entwicklungszeiten, den Zugang für Patienten transformieren und die Betriebskosten senken kann.
Die Veranstaltung findet am 13. Januar 2025 im Marines' Memorial Club & Hotel statt und wird Panelisten wie den globalen Chief Medical Officer von Microsoft, Dr. David Rhew, den CIO von Tevogen.AI, Mittul Mehta, und Dr. Sean Tunis von Rubix Health umfassen. Die Sitzung wird die Verwendung fortschrittlicher KI-Fähigkeiten von Tevogen.AI bei der Entwicklung präziser T-Zell-Therapien für Infektionskrankheiten, Krebs und neurologische Störungen hervorheben.
- None.
- None.
WARREN, N.J., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today the company will host an AI panel during the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. The panel, titled "AI in Biopharma: Next Frontier of Medical Innovation," will explore the transformative potential of artificial intelligence in the biopharma industry. Panelists will include Dr. David Rhew, Global Chief Medical Officer & VP of Healthcare of Microsoft (Nasdaq: MSFT), Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, and Dr. Sean Tunis, Principal of Rubix Health.
The discussion will highlight how AI-driven technologies can revolutionize drug discovery, accelerate development timelines, enhance patient accessibility, foster quicker innovation, and significantly reduce operating costs. Attendees can expect insights into how Tevogen.AI is leveraging advanced AI capabilities to advance precision T cell therapies for infectious diseases, cancers, and neurological disorders.
Event Details
Date:
Monday, January 13, 2025
Location:
Marines' Memorial Club & Hotel, 609 Sutter St, San Francisco, CA 94102
Time (PST):
2:00 PM – 2:30 PM – AI in Biopharma: Next Frontier of Medical Innovation
2:30 PM – 3:15 PM – Afternoon Coffee Break
3:15 PM – 4:00 PM – Pioneering the Economics of Health: Balancing Access and Outcomes
4:00 PM – 6:00 PM – Reception and Cocktails
For inquiries regarding additional event details, please contact communications@tevogen.com.
About Tevogen Bio
Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.
Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
What is the focus of Tevogen Bio's AI panel at the 2025 J.P. Morgan Healthcare Conference?
Who are the key speakers at Tevogen Bio's (TVGN) AI panel event?
When and where is Tevogen Bio's AI panel taking place?
How is Tevogen Bio (TVGN) implementing AI in their business operations?
